Sunshine Lake Pharma (HEC)
Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer.
Overview
Sunshine Lake Pharma, part of the HEC (Dongyangguang) group in Dongguan, Guangdong, is a Chinese pharmaceutical company with antiviral, metabolic and oncology pipelines. In cancer it is developing clifutinib, a small-molecule FLT3 inhibitor in a phase 3 trial for FLT3-mutated acute myeloid leukaemia, and lerotinib, a small-molecule kinase inhibitor in a phase 3 trial for oesophageal cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the group website.
Scorecard
All companies- phase 3 +6
- modalities +2
- registry trials +3
Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.
Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.
Similar pages
not linked directly; found by shared links- CompanyAP Biosciences
Shares Oesophageal cancer and the tag ctgov-sponsor.
- CompanyOrca Biosystems
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyTreadwell Therapeutics
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyOncoVerity
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyMolecular Partners
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Oesophageal cancer and the tag ctgov-sponsor.
- CompanyMiltenyi Biomedicine
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Oesophageal cancer and the tag ctgov-sponsor.